We and others have recently identified a novel paradigm of early emergence of adaptive subpopulation of EGFR-mutant lung cancer cells in escape against the corresponding targeted inhibitor from the parental drug-sensitive cell population within a very “early” time-window only days after therapy initiation [13, 26]. This evidence concerns the gene EGFR and lung carcinoma.